🇺🇸 Yunnan Baiyao in United States

23 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 23

Most-reported reactions

1. Pneumonia — 4 reports (17.39%)
2. Anaemia — 3 reports (13.04%)
3. Cardiac Failure — 2 reports (8.7%)
4. Haemoptysis — 2 reports (8.7%)
5. Interstitial Lung Disease — 2 reports (8.7%)
6. Liver Injury — 2 reports (8.7%)
7. Neutrophil Count Decreased — 2 reports (8.7%)
8. Pruritus — 2 reports (8.7%)
9. Pyrexia — 2 reports (8.7%)
10. Upper Gastrointestinal Haemorrhage — 2 reports (8.7%)

Source database →

Frequently asked questions

Is Yunnan Baiyao approved in United States?

Yunnan Baiyao does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Yunnan Baiyao in United States?

Peking University Third Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.